Hepatitis Treatment News : Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » March 2013


March 11, 2013

Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders

CROI 2013An interim analysis showed that two second-generation, direct-acting antiviral hepatitis C virus (HCV) therapies simeprevir and sofosbuvir led to high cure rates in people who had previously failed a hep C therapy. Representatives from Janssen Pharmaceuticals announced findings from this Phase IIa open-label COSMOS study at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. In the study, the protease inhibitor simeprevir (TMC435), given once daily along with Gilead Sciences’ investigational nucleotide inhibitor sofosbuvir (GS-7977), with or without ribavirin for 12 and 24 weeks. All 80 study participants had genotype 1 of hep C, mild to moderate liver fibrosis and were prior null-responders to antiviral treatment.  

The study randomly divided the participants into four arms:

  • 15 took simeprevir and sofosbuvir for 24 weeks.
  • 24 took simeprevir, sofosbuvir plus ribavirin for 24 weeks.
  • 15 took simeprevir and sofosbuvir for 12 weeks.
  • 27 took simeprevir, sofosbuvir plus ribavirin for 12 weeks.
In the 24-week arms, 66.7 percent of those taking ribavirin (one patient dropped out of the study because of an adverse event, and another person withdrew consent) and 100 percent of those without ribavirin achieved a sustained virologic response four weeks after completing therapy (SVR4, considered a cure). Among those in the 12-week arms, 96.3 percent of those taking ribavirin and 92.9 percent of those taking the regimen without ribavirin achieved an SVR4.

To read the conference abstract, click here.

Search: simeprevir, sofosbuvir, null-responder, hepatitis C, second-generation direct-acting antiviral, ribavirin, Conference on Retroviruses and Opportunistic Infections, CROI, TMC435, GS-7977.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Should Medicaid limit access to new hep C drugs?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.